At the time of writing, Galera Therapeutics Inc [GRTX] stock is trading at $0.22, down -6.89%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The GRTX shares have gain 13.33% over the last week, with a monthly amount glided 21.23%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 14, November 2023, Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates. In a post published today on Yahoo Finance, FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued.
From an analyst’s perspective:
Galera Therapeutics Inc [NASDAQ: GRTX] stock has seen the most recent analyst activity on August 10, 2023, when Piper Sandler downgraded its rating to a Neutral and also revised its price target to $0.50 from $6. Previously, BTIG Research downgraded its rating to Neutral on October 19, 2021. On October 19, 2021, downgrade downgraded it’s rating to Underperform and revised its price target to $2 on the stock. Credit Suisse upgraded its rating to a Outperform and raised its price target to $15 on December 16, 2020. H.C. Wainwright started tracking with a Buy rating for this stock on December 07, 2020, and assigned it a price target of $15. In a note dated December 02, 2019, Credit Suisse initiated an Neutral rating.
For the past year, the stock price of Galera Therapeutics Inc fluctuated between $0.09 and $3.59. Galera Therapeutics Inc [NASDAQ: GRTX] shares were valued at $0.22 at the most recent close of the market.
Analyzing the GRTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -2.06, Equity is 0.69 and Total Capital is -2.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.1973 points at the first support level, and at 0.1769 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.2340, and for the 2nd resistance point, it is at 0.2503.
Galera Therapeutics Inc [GRTX] reported earnings per share of -$0.28 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.4/share, meaning a difference of $0.12 and a surprise factor of 30.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.48 per share as compared to estimates of -$0.38 per share, a difference of -$0.1 representing a surprise of -26.30%.
Ratios To Look Out For
It is important to note that Galera Therapeutics Inc [NASDAQ:GRTX] has a current ratio of 2.47. In addition, the Quick Ratio stands at 2.47 and the Cash Ratio stands at 1.93.
Transactions by insiders
Recent insider trading involved Schneid Yair, 10% Owner, that happened on Feb 08 when 0.15 million shares were purchased. 10% Owner, Schneid Yair completed a deal on Feb 07 to buy 0.17 million shares. Meanwhile, 10% Owner Schneid Yair bought 25000.0 shares on Feb 06.
